/MRVL.V
MRVL.V Stock - Marvel Biosciences Corp.
Healthcare|BiotechnologyTSXV
$0.14-3.33%
$0.01 (-3.33%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.24
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.16
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MRVL.V
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.14 – $0.15
TARGET (TP)$0.17
STOP LOSS$0.13
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.91
52W High$0.40
52W Low$0.07
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-547,366 | N/A | $-887,516 | $-1,377,160 | $-613,099 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-1,248,683 | $-1,224 | $-2,318,933 | $-2,543,968 | $806,333 |
| Net Income | $-2,211,468 | $-1,650 | $-2,291,389 | $-2,554,139 | $-3,039,346 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.05 | $-41.30 | $-0.06 | $-0.08 | $-0.09 |
Company Overview
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MRVL.VBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q4 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q4 24
No data
Q4 24
No data
Q1 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 18, 2025 | — | $-0.01 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-0.01 | — | — |
Q4 2024 | Dec 16, 2024 | — | $-0.01 | — | — |
Q4 2024 | Oct 31, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 10, 2024 | — | $-0.01 | — | — |
Q1 2024 | Feb 15, 2024 | — | $-0.01 | — | — |
Q4 2023 | Dec 18, 2023 | — | $-0.01 | — | — |
Q4 2023 | Nov 24, 2023 | — | $-0.03 | — | — |
Q2 2023 | Jun 23, 2023 | — | $-0.01 | — | — |
Q2 2023 | Apr 30, 2023 | — | $-0.02 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.01 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-0.02 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.02 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-0.03 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-0.10 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-0.01 | — | — |
Q4 2020 | Oct 31, 2020 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about MRVL.V
What is MRVL.V's current stock price?
Marvel Biosciences Corp. (MRVL.V) is currently trading at $0.14 per share. The stock has moved -3.33% today.
What is the analyst price target for MRVL.V?
No analyst price targets are currently available for this stock.
What sector is Marvel Biosciences Corp. in?
Marvel Biosciences Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSXV exchange.
What is MRVL.V's market cap?
Marvel Biosciences Corp. has a market capitalization of $0.01 billion, making it a small-cap company.
Does MRVL.V pay dividends?
No, Marvel Biosciences Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBETR.CN
BetterLife Pharma Inc.
$0.05
Mkt Cap: $0.0B
BIOV.CN
BioVaxys Technology Corp.
$0.25
Mkt Cap: $0.0B
BLAB.CN
Britannia Life Sciences Inc.
$0.09
Mkt Cap: $0.0B
CHS.V
Comprehensive Healthcare Systems, Inc.
$0.58
Mkt Cap: $0.0B
DHB.V
Delivra Health Brands Inc.
$0.23
Mkt Cap: $0.0B
GLOW.CN
Glow Lifetech Corp.
$0.06
Mkt Cap: $0.0B
MDMA.CN
Pharmala Biotech Holdings Inc.
$0.12
Mkt Cap: $0.0B
MPH.V
Medicure Inc.
$1.25
Mkt Cap: $0.0B
PHRM.CN
PharmaTher Holdings Ltd.
$0.10
Mkt Cap: $0.0B
TRIP.CN
Red Light Holland Corp.
$0.03
Mkt Cap: $0.0B
Explore stocks similar to MRVL.V for comparison